Sun Pharma performed resiliently, driven by strong prescription momentum in India, *over or under performance to benchmark index strategic rural field force expansion and focused execution in its US specialty business. The management is actively steering pipeline progression with regulatory filings across key therapy areas backed by sustained research and development intensity. The company maintains a calibrated stance on US manufacturing, given adequate capacity and exemption from the current tariff measures. Notably, its firstmover positioning in India's GLP-1 space and accelerated launch of readiness for...